Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma Yair Lotan, M.D., Paul OʼSullivan, Ph.D., Jay D. Raman, M.D., Sharokh F. Shariat, M.D., Laimonis Kavalieris, Ph.D., Chris Frampton, Ph.D., Parry Guilford, Ph.D., Carthika Luxmanan, Ph.D., James Suttie, Ph.D., Henry Crist, M.D., Douglas Scherr, M.D., Scott Asroff, M.D., Evan Goldfischer, M.D., M.B.A., Jeffrey Thill, M.D., David Darling, M.B.A. Urologic Oncology: Seminars and Original Investigations Volume 35, Issue 8, Pages 531.e15-531.e22 (August 2017) DOI: 10.1016/j.urolonc.2017.03.008 Copyright © 2017 The Authors Terms and Conditions
Fig. 1 Standards for Reporting of Diagnostic Accuracy (STARD) diagram for patient recruitment and enrollment. Urologic Oncology: Seminars and Original Investigations 2017 35, 531.e15-531.e22DOI: (10.1016/j.urolonc.2017.03.008) Copyright © 2017 The Authors Terms and Conditions
Fig. 2 Receiver operating curves for the Cxbladder Monitor test and comparator urine tests. Dashed lines represent the performance characteristics of the Cxbladder Monitor test. Urologic Oncology: Seminars and Original Investigations 2017 35, 531.e15-531.e22DOI: (10.1016/j.urolonc.2017.03.008) Copyright © 2017 The Authors Terms and Conditions